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Abstract
HE3286, 17a-ethynyl-5-androstene-3b,7 b,1 7 b-triol, is a novel synthetic compound related to the endogenous sterol 5-
androstene-3b,7 b,1 7 b-triol (b-AET), a metabolite of the abundant adrenal steroid dehydroepiandrosterone (DHEA). HE3286
has shown efficacy in clinical studies in impaired glucose tolerance and type 2 diabetes, and in vivo models of types 1 and 2
diabetes, autoimmunity, and inflammation. Proteomic analysis of solid-phase HE3286-bound bead affinity experiments,
using extracts from RAW 264.7 mouse macrophage cells, identified 26 binding partners. Network analysis revealed
associations of these HE3286 target proteins with nodes in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways
for type 2 diabetes, insulin, adipokine, and adipocyte signaling. Binding partners included low density lipoprotein receptor-
related protein (Lrp1), an endocytic receptor; mitogen activated protein kinases 1 and 3 (Mapk1, Mapk3), protein kinases
involved in inflammation signaling pathways; ribosomal protein S6 kinase alpha-3 (Rsp6ka3), an intracellular regulatory
protein; sirtuin-2 (Sirt2); and 17b-hydroxysteroid dehydrogenase 1 (Hsd17b4), a sterol metabolizing enzyme.
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Introduction
b-AET is a metabolite of dehydroepiandrosterone (DHEA), the
most abundant adrenal sterol in the human metabolome [1]. In
rodent studies, the anti-inflammatory activities of exogenous b-
AET and DHEA [2] are similar. For b-AET, anti-inflammatory
activity in rodent models of multiple sclerosis [3], ulcerative colitis
[4], lung inflammation and septic shock [2] has been reported. b-
AET also opposes certain glucocorticoid (GC) actions in vitro [5]
and decreases corticosteroid-induced bone loss in the mouse
thermal injury model [6]. Elevated levels of GC are associated
with glucose dysregulation and hyperglycemia. Since 11b-HSD1 is
involved in the formation of b-AET [7] and GC activity, increased
levels of b-AET in obese subjects may relate to the increased levels
of this enzyme in obesity [8]. This implies a negative feedback
loop, where increased 11b-HSD1 expression results in simulta-
neous amplification of GC signaling and b-AET formation, which
may function to counter undesired aspects of GC signaling and
maintain homeostasis. In conditions of GC-associated pathology,
this relationship between GC and b-AET may be unbalanced.
Furthermore, given that rodents convert DHEA and b-AED into
metabolites with significantly more sites of oxidation [9], species
differential metabolism may explain why activities observed for
these sterols have not translated into human benefit [2,9].
HE3286, an orally bioavailable synthetic compound (Figure 1),
is pharmacologically distinct from androgens, estrogens, cortico-
steroids, and peroxisome proliferators [10]. HE3286 has demon-
strated anti-inflammatory activities similar to b-AET in murine
models of ulcerative colitis [4], multiple sclerosis [4], type 1
diabetes mellitus [11], chronic obstructive pulmonary disease [12],
and rheumatoid arthritis [4,13,14,15]. All of these models involve
attenuation of NF-kB activity and decreased levels of pro-
inflammatory cytokines, including TNFa. HE3286 exhibits anti-
inflammatory and insulin sensitizing activities in preclinical db/db
and ob/ob mouse, fa/fa ZDF rat models of diabetes [10,16], and in
a rare example of species translation for sterols, in contrast to
DHEA or b-AET, HE3286 is active in impaired glucose tolerant
and type 2 diabetes mellitus human subjects [17].
In mouse macrophages, HE3286 suppressed lipopolysaccharide
(LPS)-induced nuclear factor kappa B (NF-kB) reporter gene
expression, nuclear localization, and insulin receptor substrate-1
(IRS-1) serine phosphorylation. In addition, this compound
decreased activation of the pro-inflammatory kinases IkappaB
kinase (IKK), Jun N-terminal kinase (JNK) and p38 mitogen-
activated kinase (p38 Mapk). HE3286 also attenuated tumor
necrosis factor alpha (TNFa-stimulated inflammation and TNFa-
induced adipocyte-stimulated macrophage chemotaxis [10,16].
HE3286 treatment suppressed levels of the chemokine monocyte
chemoattractant protein-1 (MCP-1), along with its cognate
receptor, C-C motif chemokine receptor-2, in white adipose tissue
[10]. Similarly, in liver and adipose tissue, HE3286 down-
regulated inflammatory cytokine/chemokine protein levels and
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diabetic fatty (ZDF) rats [16]. In obese humans with inflammation-
induced diabetes, HE3286 decreased inflammatory cytokine
production, C-reactive protein (CRP) and post-prandial glucose
levels, leading to a decrease in HbA1c. HE3286 was safe with no
drug-related side effects [18]. These properties suggest a potential
role for endogenous b-AET, which is lost during inflammation-
driven diseases, and exogenous HE3286 in limiting chronic
inflammation. Thus, HE3286 represents the first in a new class
of anti-inflammatory agents with the potential to treat chronic
inflammatory conditions. The clinical results from administering
HE3286 prompted the exploration of target proteins in the
macrophage, a cell type that is central to the activity of HE3286,
using stable isotope labeling with amino acids in culture (SILAC)
technology in RAW 264.7 mouse macrophages.
Results
There were four method variations run in the SILAC
experiments. The first and second variations, referred to as
forward (A) and reverse (B) conditions, used a solid-phase
HE3286-bead compared to non-sterol modified agarose-beads as
a control. The third variation, referred to as forward (C)
conditions, used solid-phase HE3286-bead in both light and
heavy cell preparations where the heavy cell lysate was pre-
incubated with 50 mM HE3286 as a soluble competitor. The
fourth variation, forward (D) conditions, used solid-phase
HE3286-beads with 50 mM HE3235 (NF-kB inactive), pre-
incubated in the heavy cells as a soluble competitor and was
similarly compared to DMSO buffer using solid-phase HE3286-
beads.
The number of proteins found for each experiment and the
number identified with a ratio $1.5 are delineated in Table 1. A
target decoy database of reverse sequences was used to assure a
false discovery rate of ,1%. This allowed a comparison of
different MS database search algorithms for protein identification
as there is a known difference in protein identification using
different quantification software [19]. We compared search results,
found with the Sequest database followed by DTA select
processing, with the !Xtandem database, followed by Peptide
Prophet and Protein Prophet. In general, the total number of
identified proteins was similar. However, while 874 proteins were
found in experiment 2A using !Xtandem is extremely close to the
878 discovered initially using Sequest, only 365 coordinate
identifications were established. Notably, the alternative !Xtandem
methodology, identified 577 proteins with a ratio of .1.5
compared to 372 using the Sequest/DTA analysis. We chose to
use the Sequest/DTA algorithms for comparison of separate
experiments, as we believed this would provide fewer false
positives. Within each experiment we evaluated MS/MS data
for each hit to validate the ratios used in our analysis.
Overall, the methodology initially identified 44 candidate
binding partners. These were additionally constrained by
censoring against a published list of promiscuous binding partners
that have been identified through a retrospective analysis of several
SILAC experiments [20]. The final analysis revealed 26 HE3286
binding partners that exceeded a 1.5 binding enrichment ratio
threshold, listed in Table 2. A description of protein function for
these binding partners is included in supplemental Table S1. In
theory, the resulting ratio for the 1D experiment should be $1.5 in
order for this HE3235 control experiment to uncover proteins that
non-specifically bind to sterols. However, as HE3235 is similar in
chemical structure to HE3286, there may be shared binding
targets between these synthetic sterols that can influence this
outcome by incorrectly identifying such proteins as non-specific
binding partners to HE3286.
Discussion
Specific HE3286 macrophage binding partners were revealed
through a combination of solid phase capture and SILAC-based
proteomic analysis that resulted in the identification of a set of low
abundance proteins including signal transduction-related proteins
and transcription factors. The list of specific HE3286 target
proteins is more consistent with a biological mechanism operating
through a biosystem network paradigm instead of a single target
approach. When compared to other strategies for target
identification where large lists of proteins are often identified,
SILAC affinity experiments produce relatively fewer candidates
for inspection. Because the two separate samples are combined
before processing and are subjected to an identical experimental
protocol, sample background effects are eliminated. Experimental
strategies that use soluble competitors significantly reduce the
number of potential binding partners; however, multiple binding
interactions remain. Functional analyses to establish contributions
of potential target proteins to the observed biological phenomena
are then required in order to define the most pertinent targets
associated with HE3286 biological activities.
Our hypothesis, built on in vivo and clinical evidence was that
pathways with known association to obesity and insulin resistance;
namely insulin signaling, TNFa and LPS signaling and adipose
tissue signaling resulting in the release of chemokines, should be
effected by our list of associated proteins. Data visualized as a
network can be easier to interpret than long lists of proteins,
interactions and correlations (Figure 2) [21].
Where once proteins were considered as discrete signals, it is
now recognized that many function through complex networks of
protein-protein interactions. Using our list of 26 proteins our
analysis set increased to 1,569 proteins by including proteins with
direct interactions as defined by the BioGRID protein-protein
interaction database [22]. KEGG maps for the adipocytokine, toll-
like receptor, chemokine and insulin signaling pathways [23]
reveal multiple nodes of interaction for these binding partners that
are consistent with the observed biological activities of HE3286.
The connections of the identified HE3286 binding targets to type
2 diabetes, insulin, adipokine and adipocyte signaling are clear and
Figure 1. Chemical structures of DHEA, b-AET, HE3286 and
HE3235 (negative control).
doi:10.1371/journal.pone.0032147.g001
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S1.
We have subsequently analyzed the data in light of the
biological activities and concurrent molecular changes seen with
HE3286-treatment protocols. In addition to the anti-inflammatory
activities found in preclinical models of autoimmunity and
inflammation [4,11,12,13,14,15], HE3286 decreases chronic
inflammation associated with insulin resistance in rodent models
of diabetes [10,16] and in impaired glucose tolerant and type 2
diabetes mellitus human subjects [17]. HE3286 attenuates NF-kB
and TNFa signaling and associated pro-inflammatory cytokines
and chemokines, in these settings. Based on these results, we have
focused attention on pathways that regulate NF-kB and TNFa
stimulation with elaboration of inflammatory cytokines and
chemokines. Three particularly important nodes, Lrp1, Mapk1
and Mapk3 were discovered that are consistent with mechanistic
Table 1. Comparison of the number of proteins identified and the number of protein ratios of .1.5 in representative experiments.
Exp L/H
* Conditions #Proteins #Ratios .1.5
1A .1 (Heavy+Control Bead)+(Light+3286 Bead) 400 141
1B ,1 (Light+Control Bead)+(Heavy+3286 Bead) 580 162
1C .1 (Heavy+50 uM HE3286+3286 Bead)+(Light+3286 Bead) 369 8
1D =1 (Heavy+50 uM HE3235+3286 Bead)+(Light+3286 Bead) 698 131
2A .1 (Heavy+Control Bead)+(Light+3286 Bead) 878 372
2B ,1 (Light+Control Bead)+(Heavy+3286 Bead) 919 429
2C .1 (Heavy+50 uM HE3286+3286 Bead)+(Light+3286 Bead) 942 157
*L/H: (light isotope label/heavy isotope label) expresses the expected outcome ratio for each set of conditions.
doi:10.1371/journal.pone.0032147.t001
Table 2. Gene product enrichment ratios in mus musculus RAW 264.7 monocyte/macrophage cells using SILAC-based analysis.
Gene ID IPI number Gene Product A B C D
66885 IPI00880948 Acadsb acyl-Coenzyme A dehydrogenase 50.9 5.26 1.53 2.57
80911 IPI00857891 Acox3 acyl-Coenzyme A oxidase 3, pristanoyl 46.3 4.17 1.55 3.10
11564 IPI00265471 Adsl adenylosuccinate lyase 85.3 12.5 2.10 1.90
77559 IPI00662244 Agl amylo-1,6-glucosidase, 4-alpha-glucanotransferase 23.5 7.70 1.72 1.04
12039 IPI00331555 Bckdha branched chain ketoacid dehydrogenase E1, alpha 13.7 5.26 1.52 0.98
— IPI00858053 Cherp calcium homeostasis endoplasmic reticulum 4.10 14.3 1.91 0.81
234594 IPI00880243 Cnot1 CCR4-NOT transcription complex, subunit 1 30.2 1.79 1.66 0.92
67337 IPI00116747 Cstf1 cleavage stimulation factor, 39 pre-RNA, subunit 1 45.3 12.5 2.10 0.92
319945 IPI00226787 Flad1 RFad1, flavin adenine dinucleotide synthetase 16.3 12.5 1.66 0.96
51886 IPI00123292 Fubp1 far upstream element binding protein 1 14.2 14.3 2.19 0.43
71665 IPI00387228 Fuca1 fucosidase, alpha-L- 1, tissue 40.5 12.5 2.28 *
11991 IPI00330958 Hnrnpd heterogeneous nuclear ribonucleoprotein D 4.42 16.7 1.79 0.90
50926 IPI00755892 Hnrpdl heterogeneous nuclear ribonucleoprotein D-like 24.8 1.92 5.05 0.82
15488 IPI00331628 Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 4.97 4.76 1.76 0.95
16971 IPI00119063 Lrp1 low density lipoprotein receptor-related protein 1 9.77 9.09 2.25 0.55
26394 IPI00123518 Lypla2 lysophospholipase 2 2.16 2.50 2.10 0.93
26413 IPI00119663 Mapk1 mitogen-activated protein kinase 1 18.6 6.70 1.94 1.00
26417 IPI00230277 Mapk3 mitogen-activated protein kinase 3 27.8 6.20 1.80 2.13
76890 IPI00126892 Memo1 mediator of cell motility 1 4.63 3.85 1.74 1.08
23983 IPI00128904 Pcbp1 poly(rC) binding protein 1 2.87 12.5 1.62 0.28
231329 IPI00320034 Polr2b polymerase (RNA) II polypeptide B 12.4 12.5 1.99 0.27
110651 IPI00114333 Rps6ka3 ribosomal protein S6 kinase polypeptide 3 7.57 4.17 1.60 1.02
27054 IPI00317604 Sec23b Sec23b 11.0 9.09 1.88 0.78
218811 IPI00229483 Sec24c Sec24 related gene family, member C 6.62 11.1 1.67 0.42
64383 IPI00110265 Sirt2 Sirtuin 2 51.2 8.33 1.80 1.11
19704 IPI00420949 Upf1 UPF1 regulator of nonsense transcripts 19.4 10.0 2.15 0.61
*This protein was not identified in either sample in this experiment.
doi:10.1371/journal.pone.0032147.t002
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ing activities.
Lrp1 was identified as the only surface receptor that binds to
HE3286 on RAW264.7 cells. Lrp1 is regulated by insulin signaling
[24,25] and is important in lipid clearance and glucose tolerance.
Additionally, Lrp1 signaling results in anti-inflammatory effects.
Mice with an adipocyte-specific inactivation of Lrp1 displayed
delayed postprandial lipid clearance, reduced body weight, smaller
fat stores, improved glucose tolerance, and resistance to dietary
fat-induced obesity and glucose intolerance [26]. Inactivation of
the Lrp1 intracellular NpxYxxL motif enhances post prandial
dyslipidemia and atherosclerosis, and increases proapoptotic
effects via increased secretion of TNFa in macrophages [27].
Lrp1 is one regulator of the tumor necrosis factor receptor-1
(TNFR1) and the IKK-NF-kB pathway. Lrp1 deficient macro-
phages have decreased NF-kB signaling and MCP-1 expression,
due to down-regulation of TNFR1 and inhibition of autocrine
TNFR1-initiated cell signaling [28]. Lrp1 binds Apolipoprotien E
(ApoE) [29], and ApoE induces the anti-inflammatory M2
phenotype in macrophages [30]. Lrp1 has also been shown to
interact with scaffolding and signaling proteins via its intracellular
domain in a phosphorylation-dependent manner [31].
In addition to a cell-surface interaction with Lrp1, HE3286 also
binds Mapk1 and 3, and this binding likely modulates scaffold
interactions, which allows cross-talk between Ras-Erk and Lrp1
signaling. Mapk1 and Mapk3 (Erk2, Erk1 respectively) are integral
mediators of inflammatory signal transduction that are central to
obesity. Mice deficient in a natural Erk inhibitor, p62, have a high
level of Erk activity and develop mature-onset obesity and insulin
resistance [32]. Knockout of Erk1 in these mice decreases their
adiposity and insulin resistance [33]. Activation of TLR2 and
TLR4 with fatty acids [34,35] contributes to NF-kB activation,
increased inflammation, and insulin resistance. Tpl2 kinase is up-
regulated in adipose tissue in obese mice and human subjects and
is reported to mediate NF-kB and TNFa effects upon Erk
activation [36]. Inhibitors of IKKb or TPL2 eliminated TNFa but
not insulin-mediated Erk1 and Erk2 activation and also eliminated
IRS-1 Ser636 phosphorylation stimulated by TNFa in 3T3-L1
adipocytes.
We have shown that addition of HE3286 in vitro to Mapk1 in the
presence of activated Mek1 does not affect phosphorylation
activity of Mapk1 nor does its addition to phosphorylated Mapk1
effect phosphorylation of a peptide substrate (Reading, unpub-
lished observations). This finding suggests that HE3286 binding
perturbs scaffolding of Mapk within protein complexes to
attenuate Ras-Erk signal transduction rather than by acting
through direct inhibition of the kinase’s catalytic domain. This
may be important to the safety of this molecular class as direct
inhibition of kinase catalytic activity by ATP site-dependent
inhibitors often leads to undesirable toxicities. The development of
‘‘soft drugs’’ that attenuate signaling has been suggested as an
alternative to high affinity molecular entities that neutralize
protein action.
While the Lrp1, Mapk1, and Mapk3 are arguably central to the
biological phenomena observed for HE3286, other identified
binding partners that can also significantly contribute to these
effects are enzymes central to glucose metabolism (Agl, glycogen
degradation) and fatty acid metabolism (Acadsd, short/branched
chain acyl-CoA dehydrogenase: Acox3, acyl-CoA oxidase 3;
Hsd17b4, fatty acid b-oxidase; Lypla2, lysophospholipase). Sirt2,
a protein of recent interest for its role in intracellular regulation
through a mono-ADP-ribosyltransferase activity was also identi-
fied as an HE3286 target protein. The steroidogenic enzyme
Hsd17b4 oxidation of the C-17 hydroxyl function of C-19 sterols is
known to modify the action of 17-hydroxysterols. In a pro-
inflammatory environment, oxidation of b-AET deactivates its
anti-inflammatory properties thereby permitting the cell to execute
its inflammation program. HE3286 a chemically modified version
of b-AET, should inhibit the action of this hydroxysteroid
dehydrogenase to exert an anti-inflammatory effect.
The SILAC experiments generated a list of 26 target proteins
specific to HE3286. This result of multiple target proteins is
consistent with our expectations given the diverse biological
activities for HE3286 that have been observed in separate in vitro
and in vivo models and the involvement of the identified binding
partners to these activities. Future additional functional activity
assays will serve to detail the contributions of each binding partner
to the broad anti-inflammatory, insulin-sensitizing, and lipid
regulating activities of HE3286. Experiments with Lrp1 macro-
phage knockout mice should further establish the role of HE3286
acting upon this binding partner.
Materials and Methods
Materials
All chemicals and solvents, including, L-arginine-
13C6
15N4-
HCl, L-lysine-
13C6
15N2-HCl, 4-iodobenzylamine hydrochloride,
9-fluorenylmethyloxycarbonyl chloride (FMOC-Cl), triethyl-
amine, ethanolamine, palladium diacetate, triphenyl phosphine,
cuprous iodide, piperidine, urea, iodoacetamide, ammonium
bicarbonate, Tris(2-carboxyethyl)phosphine-HCl (TCEP), sodium
chloride, formic acid, THF (anhydrous), DMF (anhydrous), and
acetonitrile (ACN, HPLC grade) were purchased from Sigma-
Aldrich (St. Louis, MO).
N-hydroxy-succinimide-activated agarose slurry (cat#26200)
and SILAC RPMI media (cat#89984) were purchased from
Thermo Scientific (Rockfield, IL). HEPES buffer was purchased
from Mediatech (Manassas, VA) and the dialyzed fetal bovine
serum (FBS) was purchased from Sigma-Aldrich (St. Louis, MO).
Figure 2. Network of a group of mixed terms using CoPub [21]
to mine PubMed literature and generate a force directed
weighted network where strongly connected terms have thick
edges.
doi:10.1371/journal.pone.0032147.g002
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The preparation of an amino analog of HE3286 for linkage to
NHS-activated agarose beads was completed using a Sonogashira
palladium cross-coupling reaction between the C-17 alkynyl group
and a FMOC protected 4-iodobenzylamine [37]. The FMOC
protecting group was removed following the cross-coupling by
heating in piperidine. The HE3286-benzyl amine was coupled to
the NHS-activated bead according to standard protocol [38]. For
evaluation of non-specific binding of proteins onto the affinity
sorbent, we also prepared control agarose beads that were
subjected to the same treatments as the HE3286-agarose beads,
except the HE3286-amine was replaced with ethanolamine.
Protein capture
The mouse macrophage cell line RAW 264.7 (ATCC CRL-2278)
cells were grown for at least 6 cell divisions in media supplemented
with 5% dialyzed FBS, in a humidified air atmosphere with 5%
CO2. All standard SILAC media preparation and labeling steps
were followed as previously described [39]. Separate RAW 264.7
cell cultures, SILAC labeled with either light or heavy amino acids,
were lysed in ice-chilled Tris buffer (50 mM, pH 8) that included
protease inhibitors. Light and heavy lysate protein concentrations
were estimated using the DC Protein Assay (Bio-Rad, Hercules CA).
Affinity enrichment mixtures were incubated overnight (4uC, 16 h)
on an end-over-end rotator, and beads were combined for work-up
following necessary individual washing steps.
Proteins enriched in the SILAC affinity pull-down experiments
were reduced and alkylated on bead, in 5 mM TCEP and 10 mM
iodoacetamide, respectively. Trypsin was then added and the vials
were incubated at 37uC overnight on a thermomixer.
Protein analysis by LC-MS
The LC/MS analysis followed a standard protocol for the
MuDPIT technique described in the referenced protocol [40].
There were 5 salt gradients flushed through the capillary column
prior to a gradient HPLC method that eluted peptides fractions
into the Mass Spec for MS and MS/MS spectra collection.
Tandem mass spectra were searched using the Sequest algorithm
(v 3.0) against the mouse database (ipi.MOUSEv368.fasta) from
the European Bioinformatics Institute (EBI).
SILAC study design
The experimental design used to identify HE2386 binding
partners in the RAW 264.7 cell proteome (Figure 3) was adapted
to this application from a previously described method [41]. For
this purpose, HE3286 was coupled by an amine substituted linker
to a solid phase agarose bead to retain proteins that could be
classified as candidate binding partners (i.e., HE3286 target
proteins). Most proteins non-specific to HE3286 were washed off
the beads and candidate binding partners that remained adsorbed
to the solid phase were subsequently released and captured for
identification. This resulting mixture will contain direct target
Figure 3. The experimental strategy for identification of proteins that bind HE3286 in the RAW 264.7 mouse macrophage
proteome. Cells are grown in light (natural isotope) growth medium or heavy medium, containing amino acids enriched in stable isotopes (
13C and
15N). Both the heavy and light lysates were incubated with small molecule loaded beads or beads without drug (control) to enrich proteins using the
drug as an affinity probe. Alternatively, the addition of a soluble form of the drug is added to compete with the affinity matrix for binding to target
proteins. Proteins bound to the affinity matrix are digested on bead to peptides and quantified by LC-MS/MS. Target proteins are identified by
analyzing the resulting abundance ratios XIClight/XICheavy.
doi:10.1371/journal.pone.0032147.g003
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(due to protein-protein interactions) such as those involved in
scaffold assembly of protein complexes. Control beads were used
in each experiment to identify non-specific absorption by the
agarose bead, and these non-specific absorbed proteins were
removed from the candidate list by subtracting the two data sets.
Thorough mixing of the solid phase with microliter quantities of
the reagents and cell extracts was an important element to reduce
the variability in each experiment. In another experiment, soluble
HE3286 was used as a competitor to inhibit bead binding of
candidate target proteins. Subtracting the soluble competitor data
set from a buffer control produced a decreased ratio (.1.5) for
HE2386-specific binding partners in comparison to the previous
list of candidate binding partners and also identified non-specific
binding proteins. The soluble competitor experiment is sensitive to
the presence of residual competitor during workup.
In a separate approach for identifying non-specific binding
proteins, the structurally similar sterol 17 a -ethynyl -5a-
androstane-3a,1 7 b-diol (HE3235), which was inactive in our in
vitro biochemical assay for NF-kB inhibition, was used as a non-
specific soluble competitor. This eliminated proteins that bound to
the solid phase with low affinity, which are presumed to be non-
specific in nature and unrelated to the observed biological activity
for HE3286. Importantly, HE3235 in the soluble competitor
experiment may compete with specific HE3286-bound target
proteins if binding sites for their respective binding partners are
structurally similar. This complication may eliminate a participat-
ing target protein and produce a false negative result. Variability
inherent in the SILAC method is resolved through experimental
repetition.
Supporting Information
Table S1 Brief description of the 26 gene products bound by
HE3286.
(XLS)
Networks S1 Interactions from the BioGRID protein-protein
interaction database (v. 3.1.74) suggest 1,569 possible proteins
under the influence of HE3286. Using this expanded set of
proteins, multiple nodes within pathways found in the KEGG
database suggest that HE3286 may be involved in various
pathways linked to inflammation. In the included three example
pathways, Adipocytokine Signaling, Insulin Signaling, and Type II
Diabetes Mellitus, nodes are highlighted in green for proteins
found in this SILAC study and nodes are highlighted in red if the
targets are involved in a protein-protein interaction. The two
column tables below each pathway list the HE3286 bound
proteins in the first column (black) while the partnered protein
(listed in BioGRID) is shown in the second column, highlighted in
the same color as in the pathway above.
(PDF)
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